April 2016

Michael Manns, MD, explains the possible link between hepatitis C and hepatocellular carcinoma.

​Anne Covey, MD, discusses options for patients with hepatocellular carcinoma (HCC) who cannot undergo resection or transplant.

Ablation is now considered a potentially curable treatment option for patients with hepatocellular carcinoma (HCC) that should be considered secondarily to transplant and resection.

The FDA has accepted an investigational new drug application for autologous genetically modified T-cells expressing affinity enhanced T-cell receptors (TCRs) specific to alpha fetoprotein (AFP) in patients with locally advanced or metastatic hepatocellular carcinoma (HCC).

Roughly 25% of patients with resectable hepatocellular carcinoma (HCC) experienced major tumor necrosis following 4 weeks of preoperative treatment with sorafenib (Nexavar).

During a preplanned interim analysis, an independent data monitoring committee recommended the continuation of the phase III METIV-HCC trial, which is assessing the safety and efficacy of tivantinib in patients with hepatocellular carcinoma (HCC) with high MET expression.

Death rates from cancer continue to drop in the United States, with one troubling exception: more people are dying from liver cancer.

Despite the widespread prevalence of hepatocellular carcinoma (HCC), effective treatment options for both primary and secondary liver tumors have remained elusive, as these tumors are difficult to manage, especially in cases where the tumor is unresectable.

The hepatic portal vein is critical to normal liver function and supplies approximately 75% of the blood supply to the liver. In the general population, portal vein thrombosis (PVT) is relatively rare, occurring with an incidence of about in 1 in 100,000 people.

Both in the United States and worldwide, the incidence of hepatocellular carcinoma (HCC) is on the rise, and, despite extensive research, sorafenib (Nexavar) remains the only FDA-approved systemic therapy available for advanced tumors.